Table 2 Clinical and laboratory features of 88 patients with the World Health Organization (WHO)-defined ‘myelodysplastic syndrome with isolated del(5q)’, stratified by the presence or absence of the JAK2V617F mutation
Variable | Entire cohort (n=88) | JAK2V617F negative (n=78) | JAK2V617F positive (n=5) | JAK2V617F unknown (n=5) | Pa-value |
|---|---|---|---|---|---|
Age in years (median and range) | 74 (28–89) | 74 (28–89) | 74 (70–80) | 79 (70–81) | 0.54 |
Sex, M/F | 28/60 | 23/55 | 3/2 | 2/3 | 0.15 |
Hemoglobin in g per 100 ml (median and range) | 9.2 (4.7–13.3) | 9.3 (4.7–13.3) | 9.1 (5.4–10.6) | 9.0 (8.2–9.2) | 0.32 |
MCV in fl (median and range) | 103 (79–130) | 102 (79–130) | 102 (92–116) | 104 (98–111) | 0.45 |
Leukocyte count × 109 cells per l (median and range) | 4.7 (1.5–27.3) | 4.7 (1.5–27.3) | 4.5 (3.5–10.7) | 5.1 (3–7.8) | 0.98 |
Absolute neutrophil count × 109 cells per l (median and range) | 2.4 (0.5–10.5) | 2.5 (0.5–10.5) | 2.1(1.7–7.0) | 3.2 (1.9–4.1) | 0.54 |
Absolute lymphocyte count × 109 cells per l (median and range) | 1.4 (0.25–18.5) | 1.3 (0.25–18.5) | 1.6 (1.2–2.1) | 1.4 (0.6–2.3) | 0.67 |
Platelet count × 109 cells per l (median and range) | 235 (47–1800) | 230(52–780) | 221 (47–1800) | 312 (70–330) | 0.89 |
Serum ferritin at diagnosis μg l−1 (median and range) | 330 (8–3599) | 320 (8–3599) | 540 (340–1432) | 330 (300–660) | 0.09 |
Transfusion need at diagnosis (%) | 61 (69) | 52 (67) | 5 (100) | 4 (80) | 0.12 |
Disease transformation (n, %) | AML (5,6) | AML (5,6) | 0 | 0 | 0.50 |
CMML (1,1) | CMML (1,1) | ||||
RAEB-2 (1,1) | RAEB-2 (1,1) | ||||
Number of deaths (%) | 60 (68) | 50 (64) | 5 (100) | 5 (100) | 0.60 |
Follow-up duration in months (median and range) | 33 (0–158) | 31 (0–158) | 35 (4–96) | 44.2 (0.4–102) | 0.61 |
